Inactive Instrument

All News IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

IceCure Medical : Company Presentation	Apr. 23	PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	Apr. 16	AQ
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	Apr. 15	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	Apr. 15	CI
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	Apr. 03	AQ
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024	Apr. 03
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 03	CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	Apr. 02	MT
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	Apr. 02	PR
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	Apr. 02	CI
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	Mar. 27	PR
Alliance Global Partners Adjusts IceCure Medical Price Target to $2.90 From $1.90, Maintains Buy Rating	Mar. 20	MT
IceCure Medical Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 20	AQ
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	Mar. 19	PR
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 19	CI
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes	Mar. 12	PR
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech and Services Conference	Mar. 08	AQ
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference	Mar. 07	PR
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024	Mar. 04	PR
IceCure Medical Ltd. Announces Results from an Independent Study	Mar. 04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

All News

Filters